KarMMa: 5-Year Follow-Up Analysis
July 8, 2025 • CAR-T Content Hub
Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, Texas, discusses findings from the 5-year follow-up analysis of the KarMMa trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. The analysis included 137 patients and demonstrated a 76.6% overall response rate, a 34% complete response rate, and a median progression-free survival of 10.8 months. Among the patients achieving a complete response or better, 17% were still in remission at the 5-year follow-up.
